Invention Grant
- Patent Title: Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
-
Application No.: US15758045Application Date: 2016-09-08
-
Publication No.: US10759790B2Publication Date: 2020-09-01
- Inventor: Michael Ohlmeyer , Nilesh Zaware
- Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- Applicant Address: US NY New York
- Assignee: Ichan School of Medicine at Mount Sinai
- Current Assignee: Ichan School of Medicine at Mount Sinai
- Current Assignee Address: US NY New York
- Agency: Heslin Rothenberg Farley & Mesiti P.C.
- International Application: PCT/US2016/050688 WO 20160908
- International Announcement: WO2017/044569 WO 20170316
- Main IPC: C07D413/04
- IPC: C07D413/04 ; C07D413/14 ; C07D401/04 ; C07D498/04 ; C07D403/04 ; C07D405/04

Abstract:
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a therapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.
Public/Granted literature
- US20180251456A1 HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS Public/Granted day:2018-09-06
Information query